KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:开放图源暂不可得 入排置信度 0.70

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.

Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira, Byoung Chul Cho, Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, Vanina Wainsztein, Elisa Ramos, Maria Del Rosario Garcia Campelo, Hiroaki Akamatsu, Danny Nguyen, Alexis B Cortot, Alona Zer, Dilek Erdem, Rachel E Sanborn, Till-Oliver Emde, Anna R Minchom, Bogdan Zurawski, Maria Lurdes Ferreira, James Chih-Hsin Yang, Melina E Marmarelis, Julia Schuchard, Jefferson Alves, Debopriya Ghosh, Gregor Balaburski, Remy B Verheijen, Liliana Ribeiro, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Natasha B Leighl

Eur J Cancer 227 115624

PMID40730077
PMCID-
DOI10.1016/j.ejca.2025.115624
发表日期2025-07-29
入排依据:The report is an original result from a Phase III randomized trial with a drug intervention for a human oncology condition. However, it is excluded because it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required; its focus is on patient satisfaction, resource utilization, and secondary safety/experience outcomes.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

INTRODUCTION: Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival. METHODS: Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib. Resource utilization and participant-reported treatment satisfaction were evaluated at cycle (C) 1 day (D) 1 and C3D1. RESULTS: Time-in-chair was substantially lower for subcutaneous versus intravenous amivantamab (C1D1: median [range], 23 min or 0.4 h [0-12.0 h] vs 6.5 h [0-24.0 h]; C3D1: 35 min or 0.6 h [0-6.6 h] vs 3.4 h [0.5-9.0 h]), as were HCP time and participant time-in-room. More participants who received subcutaneous versus intravenous amivantamab reported feeling unrestricted (C1D1, 66 % vs 29 %; C3D1, 60 % vs 42 %) or unbothered (C1D1, 69 % vs 30 %; C3D1, 71 % vs 45 %) by administration, and reported gaining time for other activities (C1D1, 36 % vs 7 %; C3D1, 37 % vs 6 %). Few participants who received subcutaneous amivantamab reported moderate-to-very severe injection-site pain (C1D1, 14 %; C3D1, 16 %), swelling (C1D1, 5 %; C3D1, 6 %), or redness (C1D1, 5 %; C3D1, 6 %). Most subcutaneous amivantamab recipients preferred and were more satisfied with its administration versus historical experience with intravenous therapies and would recommend it. CONCLUSIONS: In PALOMA-3, subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, was a preferred option for patients who received amivantamab-lazertinib.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。